Insulin Resistance in Non-diabetic Patients with Non-alcoholic Fatty Liver Disease: Sites and Mechanisms
Overview
Authors
Affiliations
Aims/hypothesis: Non-alcoholic fatty liver disease (NAFLD) has been associated with the metabolic syndrome. However, it is not clear whether insulin resistance is an independent feature of NAFLD, and it remains to be determined which of the in vivo actions of insulin are impaired in this condition.
Methods: We performed a two-step (1.5 and 6 pmol min(-1) kg(-1)) euglycaemic insulin clamp coupled with tracer infusion ([6,6-2H2]glucose and [2H5]glycerol) and indirect calorimetry in 12 non-obese, normolipidaemic, normotensive, non-diabetic patients with biopsy-proven NAFLD and six control subjects.
Results: In NAFLD patients, endogenous glucose production (basal and during the clamp) was normal; however, peripheral glucose disposal was markedly decreased (by 30% and 45% at the low and high insulin doses, respectively, p<0.0001) at higher plasma insulin levels (p=0.05), due to impaired glucose oxidation (p=0.003) and glycogen synthesis (p<0.001). Compared with control subjects, glycerol appearance and lipid oxidation were significantly increased in NAFLD patients in the basal state, and were suppressed by insulin to a lesser extent (p<0.05-0.001). The lag phase of the in vitro copper-catalysed peroxidation of LDL particles was significantly shorter in the patients than in the control subjects (48+/-12 vs 63+/-13 min, p<0.04). Lipid oxidation was significantly related to endogenous glucose production, glucose disposal, the degree of hepatic steatosis, and LDL oxidisability.
Conclusions/interpretation: Insulin resistance appears to be an intrinsic defect in NAFLD, with the metabolic pattern observed indicating that adipose tissue is an important site.
Forouzesh P, Kheirouri S, Alizadeh M Sci Rep. 2025; 15(1):8612.
PMID: 40074727 PMC: 11904216. DOI: 10.1038/s41598-024-73132-1.
Impact of segmental body composition on metabolic fatty liver disease in Chinese children.
Hu M, Sun D, Yang F, Zheng X, Wu N, Zhang H Front Endocrinol (Lausanne). 2025; 16:1505050.
PMID: 40034234 PMC: 11872705. DOI: 10.3389/fendo.2025.1505050.
Wang X, Cao Y Biomolecules. 2025; 15(2).
PMID: 40001491 PMC: 11853042. DOI: 10.3390/biom15020188.
Zhang L, Gao S, Luan Y, Su S, Zhang E, Liu J Int J Med Sci. 2025; 22(4):834-844.
PMID: 39991765 PMC: 11843148. DOI: 10.7150/ijms.104943.
Jeele M, Mohamed H, Addow R, Hassan M, Adam B Diabetes Metab Syndr Obes. 2025; 18:507-514.
PMID: 39990175 PMC: 11847411. DOI: 10.2147/DMSO.S486956.